The UK’s entire life sciences ecosystem is in peril as a trio of pharmaceutical giants—MSD, Eli Lilly, and Sanofi—publicly pull back from investing in the country. This coordinated retreat sends a powerful signal that the UK is rapidly losing its appeal as a prime location for medical research and development.
The most significant blow was MSD’s cancellation of its £1bn London research center. This was quickly followed by news that Eli Lilly had put its own London lab on indefinite hold. Capping off the bad news, Sanofi announced it has cut UK clinical trials by 50% and will not commit to new projects without major policy changes.
These companies, which invest billions globally, are turning away from the UK due to a commercial environment they deem unworkable. They cite the UK’s low spending on new drugs compared to other nations, outdated pricing mechanisms from 1999, and a uniquely high “clawback” tax on their revenues.
Prominent scientists like Sir John Bell are now warning of a mass exodus if the government doesn’t act. The sector that was once a “crown jewel” of the economy is now facing a crisis of confidence, demanding a clear and competitive government strategy to restore its fortunes.
UK Life Sciences in Peril as MSD, Eli Lilly, and Sanofi Pull Back
